Price, Consensus and EPS Surprise
EVAX (%)
Will EVAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVAX
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
EVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now
Other News for EVAX
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
Evaxion Biotech’s Innovative Cancer Vaccine Patent Progress
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
Evaxion receives positive feedback on patent application for vaccine targets
Evaxion Biotech Updates Warrant Exercise Price